IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

METCALFE, Susan Marie

Appl. No.: 10/587,995 (U.S. Nat'l Phase

of PCT/EP05/00934)

§ 371 Date: July 27, 2007

For: Method of Inducing or Modulating

Immune Response

Confirmation No.: 7016

Art Unit:

1647

Examiner:

Lockard, Jon M.

Atty. Docket: 2655.0010000/RWE/GAL

First Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed July 31, 2006 in connection with the above-captioned application.

Copies of documents **B4** to **B5** and **C11** to **C12** are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

METCALFE et al. Appl. No. 10/587,995

- 2 -

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond Attorney for Applicants Registration No. 32,893

tw. Somone

Date:

Nov. 14, 2008

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 900453_1.DOC